- This conversion is expected to eliminate
approximately 24,000 tCO2e GHG emissions annually, advancing the
company's committed carbon emission targets.
- The shift to biomass briquettes
strengthens Piramal Pharma Limited's sustainability practices and
sets a new industry standard for environmentally responsible
manufacturing.
MUMBAI,
India, Jan. 15, 2025 /CNW/ -- Piramal Pharma
Limited (NSE: PPLPHARMA) (BSE: 543635) has achieved a notable
environmental milestone at its API and intermediates manufacturing
facility in Digwal, India by
converting its coal-fired steam boiler to operate on biomass
briquettes, a renewable energy fuel source. This achievement marks
a substantial step toward Piramal's sustainability goal to reduce
Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030. The
strategic conversion at the Digwal facility will eliminate
approximately 24,000 tonnes of carbon dioxide equivalent (tCO2e)
GHG emissions annually, accounting for about 17% of the company's
total emissions.
"The transition to biomass briquettes at our Digwal
facility is a testament to our commitment to reducing our
environmental footprint while driving innovation in sustainable
manufacturing. As we align our goals with global climate action
frameworks, we will continue to contribute to a more sustainable
future for generations to come," said Nandini Piramal,
Chairperson, Piramal Pharma Limited.
Adopting biomass briquettes is a key advancement in Piramal's
sustainability journey. These briquettes are compacted blocks of
biomass materials processed and compressed under high pressure.
Biomass briquettes, made from agricultural waste, are a renewable
fuel source that supports circular economy principles by recycling
organic by-products, reducing waste, and promoting
sustainability.
"This transformation at our Digwal facility underscores our
commitment to environmental stewardship and sustainable operational
practices," said Peter DeYoung,
Chief Executive Officer of Piramal Global Pharma. "By
transitioning to biomass briquettes, we are significantly reducing
our GHG emissions and setting new industry standards for
responsible pharmaceutical manufacturing."
This initiative supports Piramal's global sustainability goals
and demonstrates how pharmaceutical companies can implement
effective climate action solutions while maintaining operational
excellence. Piramal Pharma Limited remains committed to responsible
growth through environmentally friendly practices to support a
greener future.
About Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE:PPLPHARMA I BSE:543635), offers
a portfolio of differentiated products and services through its 17*
global development and manufacturing facilities and a global
distribution network in over 100 countries. PPL includes Piramal
Pharma Solutions (PPS), an integrated contract development and
manufacturing organization; Piramal Critical Care (PCC), a complex
hospital generics business; and the India Consumer Healthcare
business, selling over-the-counter consumer and wellness products.
In addition, one of PPL's associate companies, Abbvie Therapeutics
India Private Limited, a joint venture between Abbvie and PPL, has
emerged as one of the market leaders in the ophthalmology therapy
area in the Indian pharma market.
For more information, visit: Piramal
Pharma | LinkedIn
* Includes one facility via PPL's minority investment in
Yapan Bio.
Photo:
https://mma.prnewswire.com/media/2598532/Nandini_Piramal.jpg
Photo:
https://mma.prnewswire.com/media/2598529/Peter_DeYoung_CEO_Piramal.jpg
Photo:
https://mma.prnewswire.com/media/2598531/Biomass_Briquettes_Piramal.jpg
Photo:
https://mma.prnewswire.com/media/2598530/16_TPH_Solid_Fuel_Boiler_Piramal.jpg
Logo:
https://mma.prnewswire.com/media/2538752/5117211/Piramal_Pharma_Limited_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/piramal-pharma-limited-converts-the-coal-fired-steamer-at-its-digwal-facility-to-operate-on-biomass-briquettes-advancing-decarbonization-efforts-302351503.html
SOURCE Piramal Pharma Ltd
